Enanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800
Debt
Debt-to-Equity RatioN/A
Current Ratio24.24
Quick Ratio24.24
Price-To-Earnings
Trailing P/E Ratio86.78
Forward P/E Ratio22.18
P/E GrowthN/A
Sales & Book Value
Annual Sales$102.81 million
Price / Sales14.89
Cash Flow$1.0759 per share
Price / Cash73.40
Book Value$15.80 per share
Price / Book5.00
Profitability
EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins37.63%
Return on Equity25.84%
Return on Assets24.22%
Miscellaneous
Employees89
Outstanding Shares19,380,000
Market Cap$1.53 billion
Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions
What is Enanta Pharmaceuticals' stock symbol?
Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."
How were Enanta Pharmaceuticals' earnings last quarter?
Enanta Pharmaceuticals Inc (NASDAQ:ENTA) released its earnings results on Tuesday, August, 7th. The biotechnology company reported $0.97 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.98 by $0.01. The biotechnology company earned $57.26 million during the quarter, compared to analysts' expectations of $56.59 million. Enanta Pharmaceuticals had a net margin of 37.63% and a return on equity of 25.84%. View Enanta Pharmaceuticals' Earnings History.
When is Enanta Pharmaceuticals' next earnings date?
What price target have analysts set for ENTA?
6 equities research analysts have issued 1-year price objectives for Enanta Pharmaceuticals' stock. Their predictions range from $80.00 to $133.00. On average, they anticipate Enanta Pharmaceuticals' share price to reach $108.25 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price. View Analyst Price Targets for Enanta Pharmaceuticals.
What is the consensus analysts' recommendation for Enanta Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Enanta Pharmaceuticals.
Who are some of Enanta Pharmaceuticals' key competitors?
Some companies that are related to Enanta Pharmaceuticals include Catalent (CTLT), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE), Amneal Pharmaceuticals (AMRX), GALAPAGOS NV/S (GLPG), United Therapeutics (UTHR), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH), HUTCHISON CHINA/S (HCM), Ligand Pharmaceuticals (LGND), Endo International (ENDP), Agios Pharmaceuticals (AGIO) and Taro Pharmaceutical Industries (TARO).
Who are Enanta Pharmaceuticals' key executives?
Enanta Pharmaceuticals' management team includes the folowing people:
- Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
- Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
- Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
- Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 63)
- Ms. Carol Miceli, Director of Investor Relations
Who are Enanta Pharmaceuticals' major shareholders?
Enanta Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Manhattan Co. (3.60%), Bowling Portfolio Management LLC (0.08%) and Strs Ohio (0.06%). Company insiders that own Enanta Pharmaceuticals stock include Jay R Luly, Nathalie Adda, Paul J Mellett, Tim Ocain and Yat Sun Or. View Institutional Ownership Trends for Enanta Pharmaceuticals.
Which institutional investors are selling Enanta Pharmaceuticals stock?
ENTA stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC. Company insiders that have sold Enanta Pharmaceuticals company stock in the last year include Jay R Luly, Nathalie Adda, Paul J Mellett and Tim Ocain. View Insider Buying and Selling for Enanta Pharmaceuticals.
Which institutional investors are buying Enanta Pharmaceuticals stock?
How do I buy shares of Enanta Pharmaceuticals?
Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Enanta Pharmaceuticals' stock price today?
One share of ENTA stock can currently be purchased for approximately $78.97.
How big of a company is Enanta Pharmaceuticals?
Enanta Pharmaceuticals has a market capitalization of $1.53 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.
What is Enanta Pharmaceuticals' official website?
How can I contact Enanta Pharmaceuticals?
Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]
MarketBeat Community Rating for Enanta Pharmaceuticals (NASDAQ ENTA)
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
